We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 8 for:    CIN-107

Study to Evaluate the Effect of CIN-107 on the Pharmacokinetics of the MATE Substrate, Metformin, in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05526690
Recruitment Status : Completed
First Posted : September 2, 2022
Last Update Posted : September 2, 2022
Sponsor:
Information provided by (Responsible Party):
CinCor Pharma, Inc.

Brief Summary:
This is a randomized, open-label, two-period, crossover Phase 1 to assess the impact of CIN-107 on the pharmacokinetics (PK) of metformin and the safety and tolerability of coadministration of CIN-107 and metformin as compared to metformin alone.

Condition or disease Intervention/treatment Phase
Hypertension Drug: Metformin Drug: CIN-107 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 27 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open-Label, Two-Period, Crossover Study to Evaluate the Effect of CIN-107 on the Pharmacokinetics of the MATE Substrate, Metformin, in Healthy Subjects
Actual Study Start Date : October 28, 2020
Actual Primary Completion Date : December 12, 2020
Actual Study Completion Date : December 12, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Treatment A: Immediate-release metformin

Treatment A: single 1000 mg dose of immediate-release metformin

Subjects will be randomly assigned to 1 of 2 sequences: AB or BA.

  • Treatment A: a single 1000 mg dose of immediate-release metformin; and
  • Treatment B: a single 1000 mg dose of immediate-release metformin coadministered with a 10 mg dose of CIN-107.

All study medication will be administered at 8:00 AM (±2 hours). There will be a minimum 10-day washout between administration of study drug in each treatment period.

Drug: Metformin
1000 mg dose of immediate-release metformin

Experimental: Treatment B: Immediate-release metformin coadministered with a CIN-107

Treatment B: a single 1000 mg dose of immediate-release metformin coadministered with a 10 mg dose of CIN-107

Subjects will be randomly assigned to 1 of 2 sequences: AB or BA.

  • Treatment A: a single 1000 mg dose of immediate-release metformin; and
  • Treatment B: a single 1000 mg dose of immediate-release metformin coadministered with a 10 mg dose of CIN-107.

All study medication will be administered at 8:00 AM (±2 hours). For Treatment B, the dose of CIN-107 will be administered 2 hours prior to the dose of metformin.

There will be a minimum 10-day washout between administration of study drug in each treatment period.

Drug: Metformin
1000 mg dose of immediate-release metformin

Drug: CIN-107
10 mg dose of CIN-107




Primary Outcome Measures :
  1. Maximum plasma concentration (Cmax) [ Time Frame: Up to day 3 ]
    This plasma PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites.

  2. Time to Cmax (Tmax) [ Time Frame: Up to day 3 ]
    This plasma PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites.

  3. Area under the concentration-time curve (AUC) from time 0 to 72 hours [ Time Frame: Up to day 3 ]
    This plasma PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites.

  4. Maximum plasma concentration (Cmax) of metformin [ Time Frame: Up to day 3 ]
    This plasma PK parameter will be determined for metformin.

  5. Time to Cmax (Tmax) of metformin [ Time Frame: Up to day 3 ]
    This plasma PK parameter will be determined for metformin.

  6. AUC from time 0 to the time of last quantifiable plasma concentration of metformin [ Time Frame: Up to day 3 ]
    This plasma PK parameter will be determined for metformin.

  7. AUC from time 0 to infinity of metformin [ Time Frame: Up to day 3 ]
    This plasma PK parameter will be determined for metformin.

  8. Percent of AUC extrapolated of metformin [ Time Frame: Up to day 3 ]
    This plasma PK parameter will be determined for metformin.

  9. Terminal phase elimination half-life of metformin [ Time Frame: Up to day 3 ]
    This plasma PK parameter will be determined for metformin.

  10. Cumulative amount of metformin excreted in the urine (Ae) of metformin [ Time Frame: Up to day 3 ]
    This urine PK parameter will be determined for metformin.

  11. Renal clearance (calculated as Ae/AUC) of metformin [ Time Frame: Up to day 3 ]
    This urine PK parameter will be determined for metformin.

  12. Fraction of the dose excreted renally of metformin [ Time Frame: Up to day 3 ]
    This urine PK parameter will be determined for metformin.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy subjects between the ages of 18 and 55 years, inclusive, at Screening;
  • Body mass index between 18 and 30 kg/m2, inclusive;
  • In good health based on medical/surgical and psychiatric history, physical examination, electrocardiogram (ECG), vital signs (seated and orthostatic), and routine laboratory tests (serum chemistry, hematology, and urinalysis);
  • Normal renal function, defined as estimated glomerular filtration rate ≥85 mL/min/1.73 m2 at Screening and Day -1;
  • Nonsmokers who have not used nicotine-containing products (ie, cigarettes, nicotine patch, nicotine chewing gum, or electronic cigarettes) for at least 6 months prior to Screening;

Exclusion Criteria:

  • Actively participating in an experimental therapy study; received experimental therapy with a small molecule other than CIN-107 within 30 days of the first dose of study drug or 5 half-lives, whichever is longer; or received experimental therapy with a large molecule within 90 days of the first dose of study drug or 5 half-lives, whichever is longer;
  • A personal or family history of long QT syndrome, Torsades de Pointes, other complex ventricular arrhythmias, or family history of sudden death;
  • History of, or current, clinically significant arrhythmias, as judged by the Investigator, including ventricular tachycardia, ventricular fibrillation, atrial fibrillation, sinus node dysfunction, or clinically significant heart block. Subjects with minor forms of ectopy (eg, premature atrial contractions) are not necessarily excluded and may be discussed with the Medical Monitor for inclusion;
  • Prolonged QT interval corrected by Fridericia's formula (>450 msec);
  • Seated systolic blood pressure (BP) >140 mmHg and/or diastolic BP >90 mmHg or systolic BP <90 mmHg and/or diastolic BP <50 mmHg;
  • Postural tachycardia (ie, >30 bpm upon standing) or orthostatic hypotension (ie, a fall in systolic BP ≥20 mmHg or diastolic BP ≥10 mmHg upon standing);
  • Serum potassium >upper limit of normal (ULN) of the reference range and serum sodium <lower limit of normal of the reference range;
  • Aspartate aminotransferase, alanine aminotransferase, or total bilirubin values >1.2 × ULN;
  • Positive for human immunodeficiency virus antibody, hepatitis C virus antibody, hepatitis B surface antigen, or severe acute respiratory syndrome coronavirus 2 RNA;
  • Evidence or history of any clinically significant immunologic, hematologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, musculoskeletal, hepatic, psychiatric, neurologic, or allergic (including clinically significant or multiple drug allergies) disease; surgical conditions; cancer (with the exception of basal or squamous cell carcinoma of the skin and cancer that has resolved or has been in remission for >5 years prior to Screening); or any condition that, in the Investigator's opinion, may confound study procedures or results, impact subject safety, or interfere with the absorption, distribution, metabolism, or excretion of the study drug (appendectomy allowed, cholecystectomy prohibited);
  • Typical consumption of ≥14 alcoholic drinks weekly; Note: 1 drink of alcohol is equivalent to ½ pint of beer (285 mL), 1 glass of spirits (25 mL), or 1 glass of wine (125 mL).
  • Surgical procedures within 4 weeks prior to Check-In (other than minor cosmetic surgery or minor dental procedures) or planned elective surgery during the treatment period;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05526690


Locations
Layout table for location information
United States, Ohio
Medpace Clinical Pharmacology Unit
Cincinnati, Ohio, United States, 45227
Sponsors and Collaborators
CinCor Pharma, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Leela Leela Vrishabhendra, MD, MD Medpace Clinical Pharmacology Unit
Layout table for additonal information
Responsible Party: CinCor Pharma, Inc.
ClinicalTrials.gov Identifier: NCT05526690    
Other Study ID Numbers: CIN-107-114
First Posted: September 2, 2022    Key Record Dates
Last Update Posted: September 2, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Vascular Diseases
Cardiovascular Diseases
Metformin
Hypoglycemic Agents
Physiological Effects of Drugs